10.08.2011 • News

Symrise H1 Profit Decline

Symrise reported a drop in its first-half net income to €77.4 million from €88.8 million last year. This corresponds to earnings per share of €0.65 for the recent period versus €0.75 a year earlier.

However, in the first six months of the current financial year, Symrise posted an increase in group revenues of about 2 % to €811.8 million from €797.5 million in the previous year. The sales increase was 2.6% at local currency.

The company added that during the first half, Symrise's earnings picture was mainly affected by high raw material costs and currency effects. For 2011, Symrise said it continues to target an EBITDA margin of around 20%.

 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read